Atossa Therapeutics Files 8-K

TL;DR

ATOS filed an 8-K, standard update, no major news yet.

AI Summary

On January 30, 2025, Atossa Therapeutics, Inc. filed an 8-K report to disclose other events and financial statements. The filing does not contain specific details on new events or financial figures but serves as a notification of these items.

Why It Matters

This filing indicates Atossa Therapeutics is providing updates on its corporate activities and financial status to the SEC, which is standard procedure for public companies.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not contain any new material information that would immediately impact the company's risk profile.

Key Players & Entities

• Atossa Therapeutics, Inc. (company) — Registrant
• January 30, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 10202 5th Avenue NE, Suite 200 (address) — Principal Executive Offices
• Seattle, Washington (location) — Principal Executive Offices City and State
• 98125 (zip_code) — Principal Executive Offices Zip Code
• 206.588.0256 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.18 — ge on which registered Common Stock , $0.18 par value ATOS The Nasdaq Capital M

Filing Documents

• atos-20250130.htm (8-K) — 53KB
• atos-ex99_1.htm (EX-99.1) — 18KB
• img248274862_0.jpg (GRAPHIC) — 240KB
• 0000950170-25-012868.txt ( ) — 526KB
• atos-20250130.xsd (EX-101.SCH) — 28KB
• atos-20250130_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events On January 30, 2025, Atossa Therapeutics, Inc. (the "Company") issued a press release that announced the Patent Trial and Appeal Board's ("PTAB") final written decision in PGR2023-00043 which found that all claims under U.S. Patent No. 11,572,334 were unpatentable. While the Company disagrees with the decision and believes there are appealable issues, the Company will not be pursuing an appeal from the PTAB decision, given the cost and time involved. Instead, the Company intends to continue to pursue patent protection around the Company's current formulations in clinical development, including in a new Continuation Patent Application that has been filed with the U.S. Patent Office. The Company believes that its Continuation Patent Application will help it continue to refine patents on (Z)-endoxifen, potentially increasing its commercial value and competitiveness. The Company also announced the issuance of a new patent on January 21, 2025, U.S. Patent No. 12,201,591, entitled, "Sustained Release Compositions of Endoxifen", with 31 claims. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains certain information that may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We may identify these forward-looking statements by the use of words such as "expect," "potential," "continue," "may," "will," "should," "could," "would," "seek," "intend," "plan," "estimate," "anticipate," "believe," "design," "predict," "future," or other comparable words. All statements made in this Current Report on Form 8-K that are not statements of historical fact, including statements regarding data related to the (Z)-endoxifen program, the safety, tolerability and efficacy of (Z)-endoxifen, the potential of (Z)-endoxifen as a breast cancer prevention and treatment agent, the expected design and enrollment of trials and timing of data and related publications, and the potential milestones and growth opportunities for the Company, are forward-looking statements. Forward-looking statements in this Current Report on Form 8-K are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes, to differ materially from those projected or anticipated, including risks and uncertainties associated with: our ability to obtain patent coverage for our product candidates; macroeconomic conditions and increasing geopolitical instability; the expected timing of releasing data; any variation between interim or preliminary and final clinical results or analysis; actions and inactions by the FDA and foreign regulatory bodies; the outcome or timing of regulatory approvals needed by Atossa, including those needed to continue our planned (Z)-endoxifen trials; our ability to satisfy regulatory requirements; our ability to remain compliant with the continued listing requirements of the Nasdaq Stock Market; our ability to successfully develop and commercialize new therapeutics; the success, costs and timing of our d

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Number Description of Exhibit 99.1 Press release, dated January, 30 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Atossa Therapeutics, Inc. Date: February 4, 2025 By: /s/ Heather Rees Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR